Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Jeff Porter Sharman
Research Funding - Gilead Sciences
Steven E. Coutre
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
Bruce D. Cheson
Research Funding - Gilead Sciences
John M. Pagel
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Thomas J. Kipps
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Susan Mary O'Brien
Research Funding - Gilead Sciences
Eugen Tausch
Research Funding - Gilead Sciences
Karl A Kreuzer
Research Funding - Gilead Sciences
Wendy Jiang
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Mirella Lazarov
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Stephan Stilgenbauer
Research Funding - Gilead Sciences